Dyne Therapeutics, Inc. (DYN)
| Market Cap | 2.87B +168.8% |
| Revenue (ttm) | n/a |
| Net Income | -451.71M |
| EPS | -3.18 |
| Shares Out | 165.31M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,447,960 |
| Open | 17.21 |
| Previous Close | 17.37 |
| Day's Range | 17.15 - 17.97 |
| 52-Week Range | 8.06 - 25.00 |
| Beta | 1.08 |
| Analysts | Strong Buy |
| Price Target | 38.19 (+119.86%) |
| Earnings Date | May 11, 2026 |
About DYN
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incor... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for DYN stock is "Strong Buy." The 12-month stock price target is $38.19, which is an increase of 119.86% from the latest price.
News
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven ...
Dyne Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
The discussion highlighted execution on DMD and DM1 programs, with commercial launches targeted for 2026 and a robust pipeline expansion leveraging the FORCE platform. Confirmatory trials are underway, regulatory engagement remains strong, and capital is being efficiently allocated to advance FSHD and other assets.
Dyne Therapeutics Announces Initiation of Phase 3 FORZETTO Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) Ahead of Planned BLA Submission for U.S. Accelerated Approval
- 72-week trial will enroll approximately 90 participants; first site now open for enrollment - - Primary endpoint is rise from floor (RFF) velocity with multiple secondary endpoints to assess muscle ...
Dyne Therapeutics to Participate in Upcoming Investor Conferences
WALTHAM, Mass., May 13, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven...
Dyne Therapeutics Slides: AGM presentation
Dyne Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 13, 2026.
Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights
- Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 -
Dyne Therapeutics Quarterly report: Q1 2026
Dyne Therapeutics has published its Q1 2026 quarterly earnings report on May 11, 2026.
Dyne Therapeutics Earnings release: Q1 2026
Dyne Therapeutics released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.
Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting
- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier -
Dyne Therapeutics Proxy statement: Proxy filing
Dyne Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Dyne Therapeutics Proxy statement: Proxy filing
Dyne Therapeutics filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Dyne Therapeutics Proxy statement: Proxy filing
Dyne Therapeutics filed a proxy statement on April 9, 2026, providing details for shareholder voting and corporate governance matters.
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
- Poster on previously shared positive results from DELIVER clinical trial in Duchenne muscular dystrophy (DMD) contextualizes observed clinical measures of functional improvement for managed care exp...
Dyne Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
The company anticipates a pivotal year in 2026, with commercial launch preparations for DMD and a robust pipeline of eight clinical programs. Positive DMD data, regulatory alignment, and a differentiated platform support confidence in upcoming approvals and market entry.
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
- HARMONIA trial will assess multi-system efficacy, safety and tolerability of z-basivarsen in DM1 - - 48-week trial will enroll approximately 150 individuals, and first sites are now open for enroll...
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
- New analyses out to 24-months showed improvement in heart and lung function compared to expected declines in DMD natural history - - Data expand on previously reported results demonstrating that z-r...
Dyne Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
FORCE platform clinically validated in DMD and DM1, enabling a robust pipeline of eight rare muscle disease programs. Zirasatersen shows strong efficacy and safety, with commercial launch planned for early 2026 and DM1 to follow. Market expansion includes four additional DMD exons, tripling addressable patients.
Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
- Planned submission for U.S. Accelerated Approval of z-rostudirsen on track for Q2 2026; potential launch in Q1 2027 -
Dyne Therapeutics Earnings release: Q4 2025
Dyne Therapeutics released its Q4 2025 earnings on March 2, 2026, summarizing the period's financial results.
Dyne Therapeutics Annual report: Q4 2025
Dyne Therapeutics has published its Q4 2025 annual report on March 2, 2026.
Dyne Therapeutics Annual report: Q4 2025
Dyne Therapeutics has published its Q4 2025 annual report on March 2, 2026.
Dyne Therapeutics Slides: Corporate presentation
Dyne Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 2, 2026.
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference
- Late-breaking poster to feature new positive cardiopulmonary function results from the DELIVER trial of z-rostudirsen in DMD -
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors, e...
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1
- Zeleciment basivarsen (z-basivarsen) demonstrated sustained functional improvement across multiple clinical measures in the ongoing ACHIEVE clinical trial - - Expect to complete enrollment in ACHIEV...